- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05530967
Assessing the Validity of the PAP Problems Triage Tool in Patients With PAP Treatment for Obstructive Sleep Apnea (TriagingTool)
Assessing the Structure and Validity of the PAP Problems Triage Tool in Patients With Newly-Initiated PAP Treatment for Obstructive Sleep Apnea
Study Overview
Status
Conditions
Detailed Description
This study is a one-group observational design that uses a TT questionnaire and abstraction of PAP use data from a clinically available interface (Somnoware™). Consecutive adults with OSA and recommended to PAP treatment at the Fontana Medical Sleep Center will be invited to the study. Once the patient has been prescribed PAP therapy and has indicated their willingness to participate the TT will be sent digitally from Somnoware™. Participants will receive the TT in accordance to the next time interval defined by the study protocol. A randomly selected sub-group of participants will automatically receive an animated education video delivered digitally from Somnoware™. These videos will provide targeted information for self-managing the endorsed PAP problem.
Diagnostic polysomnogram (PSG) or home sleep apnea test (HSAT) data will be abstracted from Somnoware™. Daily PAP data will be abstracted from Somnoware™ for the first 35-days of PAP use. Demographic data will also be abstracted at day 35 (from the patient's clinical intake questionnaire and electronic health record).
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Kaiser Permanente Member (KP insured)
- OSA diagnosis by polysomnogram or Home Sleep Apnea Test with Apnea Hypopnea Index ≥ 15 events/hour
- PAP naïve
- Able to consent to participate
- Fluent or proficient with English
- Accepts PAP for home treatment
Exclusion Criteria:
- Chronic respiratory failure requiring Oxygen supplementation
- PAP device other than a PAP or AutoPAP (i.e., bilevel PAP)
- Pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Triaging Tool
|
This intervention uses questionnaire at three-time intervals (i.e., days 5, 10, and 30) and abstraction of PAP use data (days 1 - 35). Consecutive adults with moderate-severe OSA and recommended to PAP treatment will be invited to the study. Once the patient has been prescribed PAP therapy a research associate will call the patient before receiving their new PAP device. The research associate will utilize an IRB approved telephone script to discuss study details, conduct eligibility screening (inclusion/exclusion criteria), and to ask whether the patient is interested in participating. The research associate will then send the patient an IRB approved digital information sheet. The information sheet will provide the patient an option to mark "Yes" if they are willing to participate in the study or "No" if they are not willing. Patients who indicate their willingness to participate will receive the Triage Tool in accordance with the study protocol. |
|
Experimental: Video Education
|
This intervention uses questionnaire at three-time intervals (i.e., days 5, 10, and 30) and abstraction of PAP use data (days 1 - 35). Consecutive adults with moderate-severe OSA and recommended to PAP treatment will be invited to the study. Once the patient has been prescribed PAP therapy a research associate will call the patient before receiving their new PAP device. The research associate will utilize an IRB approved telephone script to discuss study details, conduct eligibility screening (inclusion/exclusion criteria), and to ask whether the patient is interested in participating. The research associate will then send the patient an IRB approved digital information sheet. The information sheet will provide the patient an option to mark "Yes" if they are willing to participate in the study or "No" if they are not willing. Patients who indicate their willingness to participate will receive the Triage Tool in accordance with the study protocol.
A randomly selected sub-group of participants (n=30) will also receive an animated education video that provides targeted information and encouragement for self-managing your PAP problem(s).
Patients in this sub-group will be asked to view a maximum of 2 different videos that are less than 2 minutes in duration.
These videos are aligned with practice guideline recommendations for addressing PAP problems early in treatment.
The videos will be sent digitally from Somnoware™.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Factor Analysis
Time Frame: 30 days
|
Investigate the factor structure of the TT, an exploratory factor analysis (EFA) will be conducted.
A forced six-factor EFA using a varimax rotation will be conducted to determine the factor loadings on six sub-scales and to determine whether the EFA factors are similar to the theoretically derived categories from the original TT instrument.
Data from the TT collected at day 5 will be used for the factor analysis as we expect higher response rate at this first data collection endpo
|
30 days
|
|
Triaging Tool Validity
Time Frame: 30 days
|
Concurrent validity will assess the extent to which TT scores are related to concurrent PAP use.
This will be established based on Pearson product moment correlation coefficients (for continuous PAP use [hours/night]) and Point Biserial correlations (for PAP non-adherence, defined as <4 hours/night of use, on average) at three intervals: day 5 (PAP use on days 1-5), day 10 (PAP use on days 6-10), and day 30 (PAP use on days 11-30).
|
30 days
|
|
Triaging Tool Predictive Validity
Time Frame: 30 days
|
To determine the TT accuracy for predicting PAP non-adherence (defined as <4 hours/night of use, on average) receiver operating characteristic (ROC) curves and respective area under the curve (AUC) with 95% confidence interval (CI) will be estimated using PAP TT subdomain scores as predictors for PAP non-adherence within 5 days post-TT score data collection.
As TT data will be collected at 3 intervals (i.e., days 5, 10, and 30) and considering the 6 subdomains from the TT scale, a total of 18 ROCs/AUCs will be estimated.
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in PAP Use Utilizing Video Education
Time Frame: 5 days
|
Unadjusted, descriptive analysis will be conducted to explore acute changes in PAP use immediately after intervention delivery.
Change in PAP use will be assessed by computing the difference (delta) in PAP use (mean, hours/night) for the 5 consecutive days pre- and post-VE.
Positive delta values will indicate greater PAP use post-intervention delivery.
|
5 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KPSleep-006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obstructive Sleep Apnea (OSA)
-
Mayo ClinicEnrolling by invitationObstructive Sleep Apnea | OSA | Obstructive Sleep Apnea (OSA)United States
-
Hong Kong Metropolitan UniversityQueen Mary Hospital, Hong KongNot yet recruitingObstructive Sleep Apnea (OSA)
-
Hospital San Pedro de LogroñoFundacion Rioja SaludNot yet recruitingObstructive Sleep Apnea (OSA)Spain
-
ResMedNot yet recruiting
-
Fondazione Don Carlo Gnocchi OnlusCompletedOSA - Obstructive Sleep ApneaItaly
-
Universidade Federal de PernambucoEnrolling by invitationSleep | Obstructive Sleep Apnea (OSA)Brazil
-
University of California, San DiegoNational Heart, Lung, and Blood Institute (NHLBI); Powell Mansfield Inc.RecruitingHealthy Volunteers | OSA | Obstructive Sleep Apnea (OSA) | ElectromyographyUnited States
-
The Hospital for Sick ChildrenFisher and Paykel HealthcareNot yet recruitingObstructive Sleep Apnea (OSA)Canada
-
ResMedNot yet recruitingObstructive Sleep Apnea (OSA)
-
MetroHealth Medical CenterNational Heart, Lung, and Blood Institute (NHLBI); University of Pittsburgh; MetroHealth...Not yet recruitingObstructive Sleep Apnea (OSA)United States
Clinical Trials on TT
-
Uludag UniversityCompleted
-
TransThera Sciences (Nanjing), Inc.Completed
-
TransThera Sciences (Nanjing), Inc.Completed
-
TransThera Sciences (Nanjing), Inc.Completed
-
Tel-Aviv Sourasky Medical CenterCompletedMultiple SclerosisIsrael, United States
-
TransThera Sciences (Nanjing), Inc.CompletedCholangiocarcinoma | FGFR2 Gene Mutation | FGFR2 Fusion | FGFR1 Alteration | FGFR3 AlterationUnited States
-
TransThera Sciences (Nanjing), Inc.RecruitingB-Cell MalignanciesUnited States
-
TransThera Sciences (Nanjing), Inc.CompletedAdvanced Solid TumorsTaiwan
-
GlaxoSmithKlineCompletedInfections, Meningococcal
-
National Institute of Allergy and Infectious Diseases...CompletedBacterial Infections | Group B StreptococcusUnited States